Clinical

Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.

Circumstantial and direct evidence, including a review of twin and backtracking studies, demonstrate potential prenatal development of acute childhood leukemias.

This systemic review determined telemedicine to be as effective as in-person appointments for the follow-up of patients with atopic dermatitis (AD).

House Republicans voted to ban quality-adjusted life years (QALYs) from being used as a drug pricing metric in federal health programs; insurance executives disapproved of newly proposed 2025 Medicare Advantage (MA) rates; patients with long COVID enrolled in an online exercise program said their health improved more than people who received standard care.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses T-cell engager therapies in the diffuse large B-cell lymphoma (DLBCL) landscape.

Dr Haumschild drives a discussion surrounding the role of bruton kinase inhibitors for treating CLL and SLL.

Results show that wastewater surveillance was sufficiently sensitive to detect Monkeypox virus (mpox) cases in these large, pooled samples.

Continuous improvement was observed across the different domains of minimal disease activity criteria with guselkumab.

Dr Shamie shares her optimism in the advancement of Demodex Blepharitis treatment.

A review of insurance policies for Demodex blepharitis treatments, along with an analysis of the potential toxicities associated with these treatments.

Medical experts illustrate the impact of combination therapy for treatment of CLL and SLL.

Investigators observed an increase in the prevalence of Alzheimer disease in patients with diagnosed myasthenia gravis (MG), which indicates that MG is an independent risk factor for AD.

No causal association with psychiatric disorders was observed in patients with chronic obstructive pulmonary disease (COPD) without a smoking history, while ever-smokers with COPD had a greater risk of developing attention-deficit/hyperactivity disorder (ADHD).

A review of recent research into myelodysplastic syndromes (MDS) shows a range of potential therapeutic targets.

Light-to-moderate alcohol consumption seemed to provide greater protection against ischemic heart disease (IHD) mortality for individuals with higher socioeconomic status (SES) compared with those with lower SES, likely due to gaps in access to necessary care.

Strategies used during the COVID-19 pandemic to ensure continuity of care in people living with HIV can be used as a paradigm of adaptability during unexpected crises.

Investigators found patients receiving chemotherapy had a greater risk of a secondary primary malignancy (SPM) compared with those treated with targeted therapies or those whose chronic lymphocytic leukemia (CLL) was left untreated.

The gene therapy delandistrogene moxeparvovec-rokl, also known as Elevidys (Sarepta Therapeutics) is indicated to treat Duchenne muscular dystrophy (DMD) in ambulatory patients aged 4 to 5 years, and Sarepta recently filed supplemental data with the FDA seeking to expand the labeled indication.

Several risk factors put patients with colorectal cancer at increased risk of anastomotic leakage after elective surgery.

Natasha Halasa, MD, MPH, of Vanderbilt University Medical Center (VUMC), discusses the active population-based surveillance that the New Vaccine Surveillance Network conducts.

With their closing thoughts, the panelists provide their key takeaways from this discussion surrounding the operationalization of bispecifics.

Experts underscore cost relief of bispecific antibodies via medication assistance programs.

Compared with patients with only chronic obstructive pulmonary disease (COPD), patients with COPD and anxiety and/or depression had increased clinical and economic burden.

Efficacy against chronic lymphocytic leukemia (CLL) was seen when tested as both a single agent and in combination with antitumor antibody.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses potential shifts in the lymphoma space in the year ahead.